Intellia to Present lonvo-z Phase 3 Data

Coya Therapeutics announced that data from its global Phase 3 HAELO clinical trial of Lonvoguran ziclumeran, a CRISPR-based gene editing therapy for hereditary angioedema (HAE), will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 in Turkey — Istanbul, Turkey. Lonvoguran ziclumeran aims to be the first one-time treatment for HAE by permanently lowering kallikrein. The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the United States — Food and Drug Administration, Innovation Passport from the United Kingdom — Medicines and Healthcare products Regulatory Agency, and PRIME and Orphan Drug Designation from the European Union — European Medicines Agency and International — European Commission, respectively. Dr. Danny Cohn will present the oral data, and Dr. Henriette Farkas will present a poster on HAE patient burdens.